FDA
-
-
-
-
-
-
-
Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
-
-
-
-
-
-
Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial Officer
-
-
-
-
-
-
-
Eloxx Pharmaceuticals Reports Fourth Quarter 2022 Financial and Operating Results and Provides Business Update
-
-
-
-
-
-
-
Eloxx Pharmaceuticals Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome
-
-
-
-
-
-
-
Eloxx Pharmaceuticals Announces Opening of Clinical Trial Sites for Phase 2 Study of ELX-02 for the Treatment of Alport Syndrome
-
-
-
-
-
-
-
Eloxx Pharmaceuticals Reports Second Quarter 2022 Financial and Operating Results and Provides Business Update
-
-
-
-
-
-
-
Eloxx Pharmaceuticals Announces Therapeutic Development Award from Cystic Fibrosis Foundation
-
330,737 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

